Precision Health Clinical Trials
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Conditions: Cancer; Tumors; Neoplasms; Neoplasia
Interventions: Drug: Alectinib; Drug: Atezolizumab; Drug: Avelumab; Drug: Axitinib; Drug: Erlotinib; Drug: Vemurafenib plus Cobimetinib (combination); Drug: Trastuzumab plus Pertuzumab (combination); Drug: Trastuzumab emtansine; Drug: Vismodegib; Drug: Niraparib
Sponsors: Ulrik Lassen; Roche Pharma AG; Pfizer; GlaxoSmithKline
Recruiting
Interventions: Drug: Alectinib; Drug: Atezolizumab; Drug: Avelumab; Drug: Axitinib; Drug: Erlotinib; Drug: Vemurafenib plus Cobimetinib (combination); Drug: Trastuzumab plus Pertuzumab (combination); Drug: Trastuzumab emtansine; Drug: Vismodegib; Drug: Niraparib
Sponsors: Ulrik Lassen; Roche Pharma AG; Pfizer; GlaxoSmithKline
Recruiting
For more information, visit the Study URL.
Embryo Selection by Noninvasive Preimplantation Genetic Test
Conditions: Infertility; Chromosome Abnormality
Intervention: Diagnostic Test: Non-invasive chromosome screening(NICS)
Sponsors: Peking University Third Hospital; Jinling Hospital,Nanjing University,School Medicine; Hebei Maternity and Reproductive hospital; Northwest Women's and Children's Hospital, Xi'an, Shaanxi; The First Medical Center of Chinese People's Liberation Army General Hospital; Shengjing Hospital; First Affiliated Hospital, Sun Yat-Sen University; Reproductive & Genetic Hospital of CITIC-Xiangya; Yikon Genomics Company, Ltd; Peking University Shenzhen Hospital; The Second Hospital of Hebei Medical University; West China Second University Hospital; Second Affiliated Hospital of Wenzhou Medical University; Third Affiliated Hospital of Zhengzhou University
Recruiting
Intervention: Diagnostic Test: Non-invasive chromosome screening(NICS)
Sponsors: Peking University Third Hospital; Jinling Hospital,Nanjing University,School Medicine; Hebei Maternity and Reproductive hospital; Northwest Women's and Children's Hospital, Xi'an, Shaanxi; The First Medical Center of Chinese People's Liberation Army General Hospital; Shengjing Hospital; First Affiliated Hospital, Sun Yat-Sen University; Reproductive & Genetic Hospital of CITIC-Xiangya; Yikon Genomics Company, Ltd; Peking University Shenzhen Hospital; The Second Hospital of Hebei Medical University; West China Second University Hospital; Second Affiliated Hospital of Wenzhou Medical University; Third Affiliated Hospital of Zhengzhou University
Recruiting
For more information, visit the Study URL.
Evolution of Multiple Primary Lung Cancer (Evolution)
Conditions: Multiple Primary Lung Cancers; Lung Cancer; Non Small Cell Lung Cancer
Intervention:
Sponsors: Peking University People's Hospital; Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Not yet recruiting
Intervention:
Sponsors: Peking University People's Hospital; Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Not yet recruiting
For more information, visit the Study URL.
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Conditions: Diarrhea; Diarrhea Infectious
Intervention: Other: no intervention
Sponsors: Centre for Infectious Disease Research in Zambia; European Vaccine Initiative; Groupe de Recherche Action en Sante; European and Developing Countries Clinical Trials Partnership (EDCTP)
Recruiting
Intervention: Other: no intervention
Sponsors: Centre for Infectious Disease Research in Zambia; European Vaccine Initiative; Groupe de Recherche Action en Sante; European and Developing Countries Clinical Trials Partnership (EDCTP)
Recruiting
For more information, visit the Study URL.
Genes and Environment in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
Sponsors: Columbia University; University of Pittsburgh; Brigham and Women's Hospital
Recruiting
Intervention:
Sponsors: Columbia University; University of Pittsburgh; Brigham and Women's Hospital
Recruiting
For more information, visit the Study URL.
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
Conditions: Prostate Cancer; Advanced Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Genitourinary Cancer
Interventions: Other: Systemic therapy; Device: StrataNGS
Sponsors: University of California, San Francisco; Prostate Cancer Foundation; Strata Oncology
Recruiting
Interventions: Other: Systemic therapy; Device: StrataNGS
Sponsors: University of California, San Francisco; Prostate Cancer Foundation; Strata Oncology
Recruiting
For more information, visit the Study URL.
GEN2 Directed Cancer Immunotherapy Trial
Conditions: Hepatocellular Carcinoma; Metastatic Cancer
Intervention: Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Sponsor: GenVivo, Inc.
Recruiting
Intervention: Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Sponsor: GenVivo, Inc.
Recruiting
For more information, visit the Study URL.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Conditions: Malignant Solid Neoplasm; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ectomesenchymoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdoid Tumor of the Kidney; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Carcinoma; Recurrent WHO Grade 2 Glioma; Refractory Adrenal Gland Pheochromocytoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdoid Tumor of the Kidney; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Carcinoma; Refractory WHO Grade 2 Glioma
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Procedure: Radionuclide Imaging; Drug: Tipifarnib
Sponsor: National Cancer Institute (NCI)
Recruiting
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Procedure: Radionuclide Imaging; Drug: Tipifarnib
Sponsor: National Cancer Institute (NCI)
Recruiting
For more information, visit the Study URL.
PDAC Peripheral and Portal Vein Sampling
Condition: Pancreatic Adenocarcinoma
Intervention: Diagnostic Test: Portal vein sampling
Sponsors: The Christie NHS Foundation Trust; Manchester University NHS Foundation Trust
Recruiting
Intervention: Diagnostic Test: Portal vein sampling
Sponsors: The Christie NHS Foundation Trust; Manchester University NHS Foundation Trust
Recruiting
For more information, visit the Study URL.
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Palbociclib
Sponsors: Chinese Academy of Medical Sciences; OrigiMed
Recruiting
Intervention: Drug: Palbociclib
Sponsors: Chinese Academy of Medical Sciences; OrigiMed
Recruiting
For more information, visit the Study URL.